Breaking Down Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Financial Health: Key Insights for Investors

Peel back the headlines on Tianjin Pharmaceutical Da Ren Tang Group (600329.SS) with hard numbers: operating revenue in H1 2025 of RMB 2.645 billion (up 0.87% YoY) while flagship Suxiao Jiuxin Wan sold RMB 1.13 billion (up 5.45%) and Qingyan Dripping Pill surged 52.28% to RMB 289 million, set against a 2024 annual revenue of RMB 7.31 billion (down 11.14%) and a TTM revenue to Sept 2025 of RMB 5.37 billion (down 33.26%) partly due to the disposal of a 12% stake in Tianjin TSKF to Haleon China; profitability reads even stronger-H1 2025 net profit attributable to shareholders of RMB 1.928 billion (up 193.08% YoY), a TTM net profit margin of 66.5%, operating margin of 27.43% (Q1 2025), ROE 46.11% and ROA 4.92%-while balance-sheet metrics show cash and equivalents of RMB 3.627 billion (up 23% from Dec 31, 2024), virtually no short-term borrowings and a debt-to-equity ratio of 0.00, current ratio 2.81, quick ratio 1.36 and interest coverage 50.94, supporting liquidity and solvency even as valuation signals value (TTM P/E 9.84, forward P/E 15.17, P/S 5.70, P/B 3.39, EV/EBITDA 28.73) and market cap has risen 32.71% over the past year-read on for a chapter-by-chapter breakdown of revenue drivers, profitability mechanics, debt posture, liquidity, valuation nuances, risks from asset disposals and regulatory exposure, and the growth levers that could reshape investor outcomes.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Revenue Analysis

• Operating revenue in H1 2025: RMB 2.645 billion, up 0.87% YoY.
• Flagship product Suxiao Jiuxin Wan: RMB 1.13 billion in sales, up 5.45% YoY.
• Qingyan Dripping Pill: sales surged 52.28% to RMB 289 million.

• Suxiao Jiuxin Wan remains the largest revenue driver, contributing roughly 42.7% of H1 2025 revenue (RMB 1.13b of RMB 2.645b).
• Qingyan Dripping Pill's 52.28% growth signals strong end-market demand and successful commercialization efforts.
• Non-core transaction effects: disposal of the remaining 12% stake in Tianjin TSKF Pharmaceutical to Haleon China materially reduced consolidated top-line comparables, contributing to the TTM decline.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Profitability Metrics

• Net profit attributable to equity holders (1H 2025): RMB 1.928 billion, +193.08% YoY.
• Trailing twelve months (TTM) ending Sep 2025 - Net profit margin: ~66.5%.
• Quarter ending Mar 2025 - Operating margin: 27.43%.
• Return on Equity (ROE): 46.11%.
• Return on Assets (ROA): 4.92%.
• TTM ending Sep 2025 - Gross profit: RMB 3.507 billion on revenue of RMB 5.366 billion (gross profit margin ≈ 65.35%).

• High net profit margin (~66.5%) and gross margin (~65.35%) point to significant pricing power or favorable product mix.
• ROE of 46.11% indicates strong returns to shareholders relative to equity base; ROA of 4.92% shows more moderate asset efficiency, common in asset-light or high-margin pharma segments.
• Operating margin of 27.43% suggests effective cost management and scalable operations for the reported quarter.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Debt vs. Equity Structure

• Cash and cash equivalents (30 Jun 2025): RMB 3.627 billion - up 23% vs. 31 Dec 2024.
• Short-term borrowings (30 Jun 2025): ~RMB 7 million - down ~RMB 15 million vs. 31 Dec 2024.
• Debt-to-equity ratio: 0.00, indicating effectively no material debt relative to equity.
• Enterprise value: RMB 28.87 billion; Market capitalization: RMB 30.57 billion.
• Financial stance: Conservative - substantial cash, minimal debt, low financial risk.

• Cash coverage: Large cash buffer relative to near-zero short-term debt reduces refinancing and interest-rate risk.
• Operational flexibility: Strong ability to fund capex, M&A, or increased R&D without issuing debt.
• Shareholder leverage: Market cap exceeding enterprise value suggests net cash position; equity holders benefit from low leverage risk.

• Low financial risk profile due to minimal borrowings and a debt-to-equity of 0.00.
• Potential trade-off: conservative financing may limit financial-engineering upside (e.g., tax-efficient debt usage), while preserving stability.
• Management optionality: substantial cash enables opportunistic deployment into growth initiatives or strategic investments.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Liquidity and Solvency

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) demonstrates a solid liquidity and solvency profile based on recent reported metrics and cash-flow strengths.

• Current ratio: 2.81 - indicates ample short-term asset coverage for current liabilities.
• Quick ratio: 1.36 - shows sufficient liquid assets (excluding inventories) to meet immediate obligations.
• Interest coverage ratio: 50.94 - reflects a very strong capacity to service interest expenses from operating earnings.
• Operating cash flow: RMB 924.7 million - supports ongoing liquidity and operations.
• Short-term borrowings decreased between December 31, 2024 and June 30, 2025 - evidence of improved short-term liability management.
• Substantial cash reserves provide a buffer against financial uncertainties, enhancing solvency resilience.

• Investor takeaway: liquidity ratios well above critical thresholds and very high interest coverage reduce solvency risk for creditors and equity holders.
• Watch items: monitor working capital cycles and any shifts in short-term borrowing policy that could affect the current and quick ratios.

For additional investor context and ownership trends, see: Exploring Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Investor Profile: Who's Buying and Why?

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Valuation Analysis

Market multiples and enterprise measures paint a mixed but actionable picture for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS). Key valuation metrics as of the latest reported period are shown below, followed by succinct implications for investors.

• Trailing twelve months (TTM) price-to-earnings (P/E): 9.84 - suggests potential undervaluation relative to peers or historical levels.
• Forward P/E: 15.17 - reflects the market's expectation of earnings growth; higher than TTM P/E implies projected earnings improvement or re-rating risk.
• Price-to-sales (P/S): 5.70 - indicates how the market values each yuan of revenue.
• Price-to-book (P/B): 3.39 - shows valuation relative to net book value; useful for balance-sheet-heavy comparisons.
• Enterprise value-to-EBITDA (EV/EBITDA): 28.73 - a higher multiple that can signal a premium on cash-flow generation or lower current EBITDA.
• Market capitalization 1-year change: +32.71% - notable appreciation signaling positive investor sentiment.

Practical considerations for valuation-driven decisions:

• Compare these multiples to domestic and global pharmaceutical peers to assess relative attractiveness.
• Reconcile the low TTM P/E with the higher EV/EBITDA - investigate recent EBITDA trends, one-time items, depreciation, and capital structure.
• Validate forward earnings drivers behind the 15.17 forward P/E: product pipeline, margin expansion, M&A, or cost efficiencies.
• Monitor market-cap momentum (32.71% Y/Y) for signs of speculative expansion vs. fundamental improvement.

For context on corporate direction and strategic priorities that may underpin these valuation metrics, see: Mission Statement, Vision, & Core Values (2026) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Risk Factors

• Disposal of 12% stake in Tianjin TSKF Pharmaceutical to Haleon China

• Transaction structure risk: a sale of equity stake converts future dividend and earnings contributions into current cash. If the divestment generated, for example, RMB 400-800 million in proceeds, investors must weigh that against foregone annual EBITDA contributions (illustrative: RMB 40-80 million/year if the asset historically contributed 10%-15% of joint-venture EBITDA).
• Impact on revenue composition: reduced ownership can lower consolidated revenues and recurring margins; volatility in reported topline and operating leverage may increase for 12-24 months after closing.

• Regulatory changes in the pharmaceutical industry

• Pricing reforms and reimbursement adjustments can compress product-level gross margins by 200-800 basis points depending on product mix.
• Approval timelines: delays in new drug approvals increase R&D carrying costs; each 6-month delay on a major pipeline product can add incremental R&D and SG&A burn equal to 1-3% of annual operating expenses.

• Raw material price volatility

• A 10% rise in key API costs can reduce gross profit by ~3-6 percentage points depending on outsourcing level and pass-through pricing ability.
• Hedging and procurement timeline: companies with 3-6 months of inventory can temporarily buffer spikes but face margin squeeze if price increases persist beyond that window.

• Currency exchange risk

• Net FX exposure is driven by import of APIs and export/overseas revenue. If 20% of costs are USD-denominated, a 5% RMB depreciation would raise local-currency costs by ~1% of revenue (estimate: RMB 10-50 million impact depending on revenue scale).
• Translation exposure affects reported consolidated earnings and equity; material FX swings can shift quarterly EPS by mid-single-digit percentage points in volatile scenarios.

• Competitive pressures

• Intensifying competition from generics and multinational entrants can force price reductions of 5-15% over 12-36 months for exposed product lines.
• R&D investment requirements: to defend or grow market share, annual R&D/sales may need to rise by 0.5-2 percentage points, pressuring short-term margins.

• Economic downturns and demand elasticity

• Consumer discretionary healthcare and OTC segments can decline 3-8% in moderate recessions; hospital and chronic care products are more resilient but not immune.
• If 25% of revenue is tied to discretionary OTC lines, a 5% drop in consumer spending could translate to a 1.25% revenue hit overall (illustrative revenue loss: RMB 20-80 million depending on scale).

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) - Growth Opportunities

• Flagship product momentum: Suxiao Jiuxin Wan reported robust year-on-year retail growth, driven by expanded OTC distribution and hospital prescription uptake.
• Capital redeployment: The disposal of the 12% stake in Tianjin TSKF Pharmaceutical crystallized cash proceeds and reduced non-core exposure, enabling reallocation to core pharma operations and R&D.
• Balance sheet strength: A strong cash position provides both optionality for internal innovation and the financial firepower to pursue acquisitions or partnerships.
• International expansion: Targeting neighboring Asian markets and selected Western specialty channels offers potential to diversify revenue and reduce dependence on the domestic cycle.
• Quality and innovation: Continued investment in GMP-compliant manufacturing and clinical development supports brand trust and premium pricing potential for new formulations.
• Strategic M&A and alliances: Targeted acquisitions and joint ventures can accelerate access to new therapeutic areas, bolster manufacturing capacity, and expand distribution reach.

• Product portfolio scale-up: Continued Suxiao Jiuxin Wan distribution expansion and line extensions (e.g., new formulations, packaging for export) - watch quarterly unit sales and ASP trends.
• R&D pipeline progression: Increases in clinical-stage assets, new OTC variants, or patent filings indicate sustainable value creation - track R&D spend and disclosed trial milestones.
• Use of disposal proceeds: Management guidance on deploying proceeds (capex, M&A, share buybacks, or debt reduction) will influence near-term EPS and balance sheet resilience.
• M&A and JV activity: Acquisitions that add specialty drugs, biologics capabilities, or regional distribution networks could materially lift margins - monitor announced deals and integration success.
• International market foothold: Growth in export revenue and regulatory approvals (e.g., registration in ASEAN, MENA, or EU/US markets) will validate scaling potential beyond China.
• Quality and compliance metrics: Manufacturing capacity utilization, GMP audit outcomes, and recall-free records support premiumization and long-term brand equity.

• Suxiao Jiuxin Wan: unit sales, price per unit, channel mix (hospital vs. retail)
• Cash & short-term investments: absolute balance and free cash flow conversion
• R&D expense and pipeline milestones (IND/CTA, pivotal trials)
• M&A pipeline/announcements and integration KPIs
• Export revenue growth and number of registered overseas markets
• Gross margin and operating margin trends (to see leverage from scale and higher-value products)